President Donald Trump’s communications and travel freeze at HHS may be part of the reason an upcoming FDA advisory committee ...

FDA expands Ozempic label to include kidney disease benefits in type 2 diabetes patients. Novo Nordisk's drug can now be ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu is now approved to treat a new subset of breast cancer ...

Novo Nordisk is asking a federal appeals court to make haste on its case challenging the Inflation Reduction Act's drug ...

KFF analysis highlights that ACA marketplace insurers denied 19% of claims. Less than 1% of denials were appealed, and ...

Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and ...

Eli Lilly is discontinuing a Phase 2 relaxin treatment candidate for heart failure and chronic kidney disease, a spokesperson for the company confirmed to Endpoints News.

Another obesity biotech emerged on Tuesday morning, this time taking a different approach to the GIP antagonism story than ...

ITM-11 beats everolimus in Phase 3 GEP-NETs trial; ITM plans filing. Drug will compete with Novartis's Lutathera. Both use ...

Leap Therapeutics reported mixed results on Tuesday for an experimental treatment in gastric and colorectal cancer, announcing it is only moving forward with the latter indication. The biotech’s ...

For MASH developers, a race for cash: Akero Therapeutics aims to raise $300 million in an offering ...

In its latest move to expand its portfolio, Lantheus Holdings is spending $250 million upfront to buy radiopharma CDMO and ...